Which drug lowers cholesterol better? new study compares alirocumab and inclisiran
NCT ID NCT07615166
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two medicines, alirocumab and inclisiran, that help lower bad cholesterol (LDL-C) in people with heart disease. Researchers will use real-world data from about 124 patients to see which drug reduces cholesterol more over time. The goal is to understand how these treatments compare in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi
Bridgewater, New Jersey, 08807, United States